News & Studies Archives - Page 5 of 7 - Clinical Trial Services, UK

View PHARMExcel are delighted to announce their future collaboration with DIOSynVax to support the delivery of their forthcoming clinical trial program.

PHARMExcel are delighted to announce their future collaboration with DIOSynVax to support the delivery of their forthcoming clinical trial program.

Thursday, March 17th, 2022

This programme, (supported by CEPI funding), will provide the infrastructure to help design and select the lead antigen through proof-of-concept preclinical studies, progressing to initial clinical development through Phase I/II studies. DIOSynVax aim to establish clinical proof of concept for a novel vaccine candidate with the potential to provide broad protection against Sarbecovirus, Merbecovirus, Embecovirus and Nobecovirus.

Adopting a New Agile Approach to CRO Clinical Trial Management

Article by Trishna Champaneri, Clinical Study/Project Manager, PHARMExcel
Thursday, March 3rd, 2022

Following its reputation of excellence in delivering investigator-led studies, PHARMExcel was selected to manage the Covid-19 vaccine booster study.

New EU Clinical Trial Regulation

Article by Yvanne Enever and Dr Gita Patel
Monday, January 31st, 2022

The new EU clinical trial regulation (CTR) is set to revolutionise clinical trial processes across Europe impacting all European Member states and organisations wanting to run clinical trials across these regions. How can organisations prepare for the change and set themselves up successfully with a new CTR programme?

Yvanne Enever, Founder/CEO reflects on 2021

Tuesday, January 4th, 2022

We are pleased to say that 2021 has seen PHARMExcel busier than ever. From delivering the Worlds’ first Booster Vaccine clinical trial leading to the shaping of UK Government policy, to welcoming new, key staff appointments and undertaking several charity events for Macmillan Cancer Support, Team PHARMExcel showed dedication to the cause. As we complete…

View PHARMExcel delighted to be the selected U.K. CRO delivering this pivotal clinical trial alongside colleagues at University Southampton, Cambridge and DIOSynVax.

PHARMExcel delighted to be the selected U.K. CRO delivering this pivotal clinical trial alongside colleagues at University Southampton, Cambridge and DIOSynVax.

Friday, December 17th, 2021

PHARMExcel are pleased to announce the publication of the safety and immunogenicity data from the UK’s Covboost trial.

Monday, December 6th, 2021

Covid booster jabs will begin to be offered across the UK from next week based on JCVI decisions following COVBoost clinical trial data.

Wednesday, September 15th, 2021

View PHARMExcel, a U.K. based CRO, is delighted to have been selected as the CRO to support the COVBoost study. Data has contributed to the MHRA approval decisions

PHARMExcel, a U.K. based CRO, is delighted to have been selected as the CRO to support the COVBoost study. Data has contributed to the MHRA approval decisions

Thursday, September 9th, 2021

PHARMExcel supports recruitment of the first patient into INmuneBio’s pivotal MDS study showing promising results

Wednesday, August 25th, 2021